Beta-Hydroxybutyrate Boosts CAR T Cell Cancer Fighting Power
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
20 articles
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells โ and show bortezomib can fix it in CAR-T therapy.
New research identifies HBO1 as a key driver of cancer cell transformation and resistance to CAR-T cell therapy in ovarian cancer.
New research reveals how brain barrier variations affect cancer treatment delivery, potentially improving outcomes.
New research reveals how blood-brain barrier differences affect immunotherapy access, potentially improving brain cancer treatment.
BCG therapy for bladder cancer travels to bone marrow, reprogramming stem cells to produce enhanced immune cells that fight tumors throughout the body.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
Tucatinib-based treatment extends survival from 4.4 to 10 months for women with breast cancer that spread to brain lining.
New fusion model combines hypoxia and immune markers to predict hepatocellular carcinoma treatment success non-invasively.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
ASTER 70s trial compares treatment intensities for women 70+ with genomically high-risk breast cancer to optimize outcomes while minimizing toxicity.
New study reveals combining PARP inhibitors with bevacizumab extends progression-free survival in previously treated ovarian cancer patients.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
Japanese trial shows dual HER2 blockade with pertuzumab plus trastuzumab improves overall survival even after prior pertuzumab treatment.
B7-H3-targeted therapy HS-20093 achieved 52% response rate in small cell lung cancer and 22% in non-small cell lung cancer patients.
Redirecting glucose metabolism during T cell expansion dramatically improves cancer immunotherapy effectiveness.
New review reveals how targeting mitochondria in cancer cells could overcome immunotherapy resistance and enhance anti-tumor responses.
New approach targets specific cancer sites in advanced lung cancer patients, potentially improving outcomes.
New research reveals how the p53 tumor suppressor protein fights cancer by activating cell death pathways when oxygen levels drop.